Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels . Viradapt study, week 48 follow up and Pharmacological data.

7/25/00


Click here to start


Table of Contents

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels . Viradapt study, week 48 follow up and Pharmacological data.

Background

VIRADAPT: Trial Design

12 months Follow up Study

Patients and Methods

Patients and Methods: Statistical Analysis for the first 6 months randomized study

6 - 12 month follow-up study: Patients and Methods

Genotyping Technology

Mutations - Drug Resistance Table

Baseline Characteristics : Demographic data

Prior Antiretroviral Treatment

Baseline Characteristics-Frequency of Primary and Secondary RT mutations

Baseline Characteristics-Frequency of primary and secondary P mutations

Results

Mean changes in plasma HIV-RNA from baseline throughout 12 months in Control and Genotypic arms

Percentage of patients with plasma HIV-RNA below the limit of detection (200 copies/ml) in Control and Genotypic arms

Correlation of baseline primary protease mutations and randomization arm with changes in HIV RNA

Conclusions

Importance of Protease Inhibitor plasma levels in patients treated with Genotypic adapted therapy 

Background

Background

Study Objective

Methods

Methods

Results

PI drug levels

Correlation HIV-RNA and plasma level

Pharmacokinetic data of P.I

Optimal Drug Concentrations

Results

Efficacy analysis based on drug levels and randomization arm

Efficacy analysis based on drug levels and randomization arm

Percentage of patients with plasma HIV-RNA below the limit of detection (200 copies/ml)

Predictive factors of virological response

Conclusions

Acknowledgements

Author: jd